Particle.news
Download on the App Store

France’s First In-Utero Treatment Shrinks Fetal Vascular Tumor, Baby Avoids Intubation

Physicians used a maternal anti‑angiogenic medication proposed by a Lyon reference center after a late‑pregnancy KMS diagnosis.

Overview

  • Doctors in Mulhouse identified Kasabach‑Merritt syndrome late in the seventh month, with a neck mass severely threatening the fetus’s breathing, according to Dr. Chris Minella.
  • A specialized center in Lyon advised prenatal therapy with a drug that inhibits new blood‑vessel growth, which the mother took orally.
  • The baby, Issa, was delivered by cesarean on November 14, 2025, after the tumor shrank, and no intubation was required at birth.
  • Treating physician Alexandra Spiegel‑Bouhadid said the vascular malformation was stabilized following the prenatal intervention.
  • Issa spent about one month hospitalized after delivery, was discharged home, remains under regular follow‑up, and still has a residual facial mass while feeding and growing well.